Filtered By:
Condition: Bleeding
Countries: Sweden Health

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 18 results found since Jan 2013.

Risk of Ischemic Stroke and Major Bleeding in Patients With Atrial Fibrillation and Cancer
Background: Atrial fibrillation (AF) is an important risk factor for ischemic stroke. Cancer may increase the risk both of ischemic stroke and of bleeding. Less is known about risk of ischemic stroke and bleeding among cancer patients with AF, complicating the prevention of ischemic stroke in these patients. Methods: Register based cohort study comprising all Swedish patients hospitalized with a primary diagnosis of AF from July 1, 2005 until December 31, 2014. Patients with cancer diagnosis were compared to the rest of the cohort.
Source: Journal of Stroke and Cerebrovascular Diseases - December 26, 2019 Category: Neurology Authors: Sara Aspberg, Liyang Yu, Bruna Gigante, Karin E Smedby, Daniel E Singer Source Type: research

Alcohol-related hospitalization is associated with increased risk of ischaemic stroke among low-risk patients with atrial fibrillation
ConclusionThe presence of a previous hospitalization with an alcohol-related disease was associated with a small but significant increase in the risk of stroke among low-risk AF patients. More research about relation between alcohol use and ischaemic stroke in AF patients is warranted.
Source: Europace - February 23, 2017 Category: Cardiology Source Type: research

A clinical decision support tool for improving adherence to guidelines on anticoagulant therapy in patients with atrial fibrillation at risk of stroke: A cluster-randomized trial in a Swedish primary care setting (the CDS-AF study)
ConclusionsThe present study demonstrates that a CDS can increase guideline adherence for anticoagulant therapy in patients with AF. Even though the observed difference was small, this is the first randomized study to our knowledge indicating beneficial effects with a CDS in patients with AF. Trial registrationClinicalTrials.gov NCT02635685
Source: PLoS Medicine - March 13, 2018 Category: Internal Medicine Authors: Lars O. Karlsson Source Type: research

Potential effects on cardiometabolic risk factors and body composition by short message service (SMS)-guided training after recent minor stroke or transient ischaemic attack: post hoc analyses of the STROKEWALK randomised controlled trial
Conclusions No clear effect of 3 months daily mobile phone delivered training instructions was detected on body composition, cardiovascular biochemical risk factors or self-perceived health. Further research is needed to evaluate secondary prevention efforts in larger populations after recent stroke. Trial registration number NCT02902367.
Source: BMJ Open - October 18, 2021 Category: General Medicine Authors: Vahlberg, B. M., Lundström, E., Eriksson, S., Holmback, U., Cederholm, T. Tags: Open access, Rehabilitation medicine Source Type: research

Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries
CONCLUSIONS: Incidences of intracranial bleeding were generally lower with rivaroxaban than with SOC, whereas incidences of gastrointestinal and urogenital bleeding were generally higher. The safety profile of rivaroxaban for NVAF in routine practice is consistent with findings from randomized controlled trials and other studies.PMID:36795067 | DOI:10.1080/14740338.2023.2181334
Source: Expert Opinion on Drug Safety - February 16, 2023 Category: Drugs & Pharmacology Authors: Luis Alberto Garc ía-Rodríguez Ana Ruig ómez Tania Schink Annemarie Voss Elisabeth Smits Karin M A Swart Yanina Balabanova Kiliana Suzart-Woischnik Gunnar Brobert Ron M C Herings Source Type: research

Second death linked to potential antibody treatment for Alzheimer ’s disease
A 65-year-old woman who was receiving a promising experimental treatment to slow the cognitive decline caused by her early Alzheimer’s disease recently died from a massive brain hemorrhage that some researchers link to the drug. The clinical trial death, described in an unpublished case report Science has obtained, is the second thought to be associated with the antibody called lecanemab. The newly disclosed fatality intensifies questions about its safety and how widely lecanemab should be prescribed if ultimately approved by regulators. The woman, who received infusions of the antibody as part of the trial, s...
Source: ScienceNOW - November 28, 2022 Category: Science Source Type: news

Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation
The objective of this study was to compare effectiveness and safety between reduced dose DOACs and high TTR warfarin treatment (TTR  ≥ 70%) in NVAF. A Swedish anticoagulation registry was used in identifying eligible patients from July 2011 to December 2017. The study cohort consisted of 40,564 patients with newly initiated DOAC (apixaban, dabigatran, or rivaroxaban) (11,083 patients) or warfarin treatment (29,481 patients ) after exclusion of 374,135 patients due to not being warfarin or DOAC naïve, not being prescribed reduced dose, having previous mechanical heart valve (MHV), or being under 18 years old. The me...
Source: Journal of Thrombosis and Thrombolysis - January 6, 2023 Category: Hematology Source Type: research

Blood-thinning drugs may reduce dementia risk in people with irregular heartbeats
Conclusion If you’ve been diagnosed with AF and you have been prescribed anticoagulant treatments such as warfarin or clopidogrel, we already know they protect you against having a stroke. This study suggests they may also help to protect you against dementia. Cutting the risk of dementia for people who have a raised risk because of AF would be an exciting step forward. Unfortunately, we can’t tell from this study whether the protection against dementia was down to the anticoagulants, because of the possible effect of unmeasured confounding factors. Usually, we would want to see a randomised controlled trial (RCT) to f...
Source: NHS News Feed - October 25, 2017 Category: Consumer Health News Tags: Neurology Source Type: news

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
Conclusion Dabigatran is a cost-effective treatment in Sweden, as its incremental cost-effectiveness ratio is below the normally accepted willingness to pay limit.
Source: European Heart Journal - January 14, 2013 Category: Cardiology Authors: Davidson, T., Husberg, M., Janzon, M., Oldgren, J., Levin, L.-A. Tags: Arrhythmia/electrophysiology Source Type: research

Outcome After Endovascular Repair of Ruptured Descending Thoracic Aortic Aneurysm: A National Multicentre Study.
CONCLUSIONS: This nationwide multicentre study of patients with rDTAA undergoing TEVAR showed acceptable short- but poor long-term survival. Adequate proximal and distal aortic sealing zones are important for technical success. High risk patients and post-operative complications need to be further addressed in an effort to improve outcome. PMID: 30910493 [PubMed - as supplied by publisher]
Source: PubMed: Eur J Vasc Endovasc ... - March 21, 2019 Category: Surgery Authors: Sari H, Thomas L, Rebecka H, Anders W, Kevin M, Timothy R, Mårten F, Claes F, Björn S, Artai P, Håkan R, Tina H, Shazhad K, Jonas H, Carl-Magnus W Tags: Eur J Vasc Endovasc Surg Source Type: research

Comparison Between Ticagrelor and Clopidogrel in Elderly Patients with an Acute Coronary Syndrome: Insights from the SWEDEHEART Registry.
Conclusions: Ticagrelor use among elderly MI patients was associated with higher risk of bleeding and death compared with clopidogrel. A randomized study of ticagrelor vs clopidogrel in the elderly is needed. PMID: 32867508 [PubMed - as supplied by publisher]
Source: Circulation - August 31, 2020 Category: Cardiology Authors: Szummer K, Montez-Rath ME, Alfredsson J, Erlinge D, Lindahl B, Hofmann R, Ravn-Fischer A, Svensson P, Jernberg T Tags: Circulation Source Type: research

Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants
AbstractNew oral anticoagulants (NOACs) is the preferred treatment in secondary prophylaxis of venous thromboembolic events (VTE). The aim of this study was to investigate possible risk factors associated with major bleeding in VTE-patients treated with NOACs. In this retrospective register-based study we screened the Swedish anticoagulation registerAuricula (during 2012.01.01 –2017.12.31) to find patients and used other national registers for outcomes. Primary endpoint was major bleeding defined as bleeding leading to hospital care. Multivariate Cox-regression analysis was used to reveal risk factors. 18 219 patients wi...
Source: Journal of Thrombosis and Thrombolysis - November 2, 2020 Category: Hematology Source Type: research

Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
Publication date: Available online 25 August 2018Source: The LancetAuthor(s): Marco Valgimigli, Enrico Frigoli, Sergio Leonardi, Pascal Vranckx, Martina Rothenbühler, Matteo Tebaldi, Ferdinando Varbella, Paolo Calabrò, Stefano Garducci, Paolo Rubartelli, Carlo Briguori, Giuseppe Andó, Maurizio Ferrario, Ugo Limbruno, Roberto Garbo, Paolo Sganzerla, Filippo Russo, Marco Nazzaro, Alessandro Lupi, Bernardo CorteseSummaryBackgroundThe Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of ra...
Source: The Lancet - August 25, 2018 Category: General Medicine Source Type: research

Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication
ConclusionMost of the well-established risk factors were found to be significantly associated with bleeding events in our study. We additionally found that women had a lower incidence of bleeding. Potential biases are selection effects, residual confounding and unmeasured frailty.
Source: European Journal of Clinical Pharmacology - March 27, 2020 Category: Drugs & Pharmacology Source Type: research